ISPOR Forums
Monday, 6 November 2017
18:15 - 19:15
BREAKOUT SESSION

18:15 - 19:15
Room: Hall 3
F1: BETTER, CHEAPER, FASTER: A REPORT ON THE SCIENCE OF OPTIMIZATION FROM THE ISPOR OPTIMIZATION TASK FORCE
Moderator:

Alec Morton, PhD, Professor of Management Science, Department of Management Science, Strathclyde Business School, University of Strathclyde, Glasgow, Scotland, UK

Speakers:

Nasuh Buyukkaramikli, PhD, Scientific Researcher, Institute of Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, The Netherlands

Praveen Thokala, MASc, PhD, Research Fellow, The University of Sheffield, Sheffield, UK

Jon Tosh, MSc, PhD, Senior Health Economist, DRG Abacus, Manchester, UK

DESCRIPTION:

Planning or managing health services involves tough questions: What’s the cheapest way to protect my population against infection? the best time to start pharmacotherapy for patients with a degenerative condition? How do I ensure that my cancer patient gets the lowest radiation dose possible? That scarce organs go to those who need them most? How do you select and manage the portfolio for health technology development?

These questions can be, and often are, answered by gut feel and simple rules of thumb. But ISPOR members will want to do better, to ensure that services are planned and managed to give the very best possible value for patients and for payers. The ISPOR Optimization Task Force has reviewed current practice on the use of cutting-edge mathematical techniques which can give decision makers the assurance that the changes they make to services are not just better than current practice, but truly optimal from a mathematical perspective.

In this Forum, members of the Task Force will present material based on their good practice reports. They will present a step-by-step Checklist for critiquing and reporting optimization studies. They will also review where these tools have a demonstrated track record of use and where there are emerging opportunities to make use of new and powerful analytic techniques. For the benefit of attendees keen to get started using the methods, there will be a discussion of opportunities for skill development and the Task Force members will be on hand to share their thoughts and experiences.

Presented by ISPOR Optimization Task Force


18:15 - 19:15
Room: Hall 2
F2: METHODS AND PRELIMINARY RESULTS OF THE ISPOR ONCOLOGY HEALTH ECONOMIC MODELING SPECIAL INTEREST GROUP
Moderator:

Noemi Muszbek, MSc, Senior Research Scientist, Evidera, London, UK

Speakers:

Agnes Benedict, MSc, Executive Director, Evidera, Budapest, Hungary

Nermeen Nabil Ashoush, PhD, Lecturer in Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, The British University in Egypt, Cairo, Egypt

Hena Qureshi, BSc BA, Student, Community Health Sciences, University of Calgary, Calgary, AB, Canada

DESCRIPTION:

An update on the work of the Oncology Health Economic Modeling Working Group conducting a systematic literature review (SLR) of health utilities, resource use and costs in post-progression/post-response in advanced oncology indications (primary studies and economic evaluations). The objective of the SLR is (i) to assess current gaps, data quality issues and other challenges in eliciting/collecting, analyzing and implementing post-progression/post-response data inputs in economic evaluations and (ii) to make recommendations in collaboration with clinicians, payers, and patient representatives, for future research and approaches to overcoming these challenges.

The methods and preliminary results (selection of articles based on titles and abstracts) were presented at the ISPOR 22nd Annual International Meeting in May 2017. The forum will present the final study selection results and the preliminary findings based on extracted data. Data availability and quality will be assessed and data gaps and limitations will be identified according to indications, countries and methods for elicitation and analyses. Methods used for implementation of utility, costs and resource use data in economic evaluations will also be described, and inconsistencies between model/health technology assessment requirements and data availability and quality will be discussed. The predominant partitioned survival models assume that utilities and costs are dependent mainly on progression status. The availability of data to support and/or contradict this assumption will be assessed.

The audience will be invited to comment and provide feedback on the project. The presentation may be of interest to anyone involved in producing or using results of cost-effectiveness models of advanced oncology treatments, including health economists, members of health technology assessment bodies and manufacturers.

Presented by Oncology Health Economic Modeling – Post-Progression Working Group of the ISPOR Oncology SIG


18:15 - 19:15
Room: Clyde Auditorium (Armadillo)
F3: RARE DISEASE RESEARCH, HTA AND EVIDENCE FOR REIMBURSEMENT
Moderator:

Sandra Nestler-Parr, PhD, MPhil, MSc, Managing Director, Rare Access Ltd., London, UK

Speakers:

Ken Redekop, PhD, Associate Professor, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands

Christopher M. Blanchette, PhD, MBA, Associate Professor, University of North Carolina, Charlotte, NC, USA & VP, Precision Health Economics, Charlotte, NC, USA

Sheela Upadhyaha, BSc, Associate Director Highly Specialised Technologies, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence, London, UK

Janis Clayton, BSc, VP and General Manager UK & Ireland, PTC Therapeutics Ltd., Dublin, Ireland

DESCRIPTION:

Between 6% and 8% of people worldwide suffer from a rare disease. Although no treatments are available for most, the introduction of regulatory legislation for orphan medicinal products and the subsequent development of a rare disease policy landscape have resulted in the rise of rare disease health technologies in recent years. HTA agencies, payers and manufacturers are employing collaborative approaches to develop market access policies that address the diverse and interrelated challenges inherent to rare disease research, HTA, and reimbursement decision-making. These approaches include novel strategies for evidence generation, benefit assessment and innovative pricing models. In this session, a multi-stakeholder panel will conceptualize the challenges for research, HTA and reimbursement of rare disease health technologies, followed by an interactive panel discussion about pragmatic solutions based on real-world examples. Rare disease experts will represent academic, HTA, patient and industry perspectives. Presented by the ISPOR Rare Disease Special Interest Group
Presented by ISPOR Rare Disease Special Interest Group


18:15 - 19:15
Room: Hall 1
F4: COULD MULTI-STAKEHOLDER PARTNERSHIP IMPROVE PATIENT ACCESS TO BETTER HEALTHCARE IN LATIN AMERICA?
Moderator:

Ramiro E. Gilardino, MD, MSc, Director, Global Networks Latin America, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), Lawrenceville, NJ, USA

Speakers:

Diego F Guarin, MD, MPH, MA, Senior Director, HEOR & HTA Strategy, HEOR & HTA, Latin America, Merck-Serono, Billerica, MA, USA

Diego Rosselli, MD, Associate Professor, Clinical Epidemiology and Biostatistics Department, Pontificia Universidad Javeriana, Bogota, Colombia

Federico Augustovski, MD, MSc, PhD, Director, Health Technology Assessment & Economic Evaluations Department, Institute for Clinical Effectiveness and Health Policy (IECS), Professor of Public Health, University of Buenos Aires, Buenos Aires, Argentina

Nicola Bedlington, Secretary General, European Patients’ Forum and Co-Founder, The Patient Access Partnership PACT, Brussels, Belgium

DESCRIPTION:

Despite number of countries in Latin America are implementing healthcare reforms to improve patient access, it’s still an unmet need, especially when innovative treatments count, due to lack of economic resources, health technology assessment implementation and training of healthcare professionals among others. Some regions are implementing partnerships within stakeholders involved to improve patient access to basic and innovative health care and mitigate those inequities in this group of people, would it be possible in fragmented Latin America environment?. This forum will highlight patients and expert’s views on advancing access to health care in the region
Presented by the Latin America Consortia


18:15 - 19:15
Room: Lomond Auditorium (Loch Suite)
F5: RARE DISEASES MCDA CRITERIA IMPLEMENTATION RESULTS IN EUROPEAN COUNTRIES
Moderator:

Olha Zaliska, PhD, DSci (Pharm), Professor, The Head of Department of Management & Economy of Pharmacy and Medicine Technology, Postgraduate Faculty, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

Speakers:

John Yfantopoulos, PhD, President, ISPOR Greece Chapter, Professor, Health Economics, University of Athens, Athens, Greece

Francesco Saverio Mennini, MSc, Professor of Health Economics and Research Director, Professor of Health Economics and Research Director, CEIS Economic Evaluation and HTA (EEHTA), University Tor Vergata Roma, Rome, Italy

Tarik Catic, PhD(s), Consultant, Health Economics and Pharmacoeconomics, Sarajevo, Bosnia

Rok Hren, PhD, MSc IHP(HE), President, ISPOR Slovenia Chapter, Assistant Professor, Institute of Mathematics, Physics and Mechanics, Ljubljana, Slovenia

DESCRIPTION:

Rare disease Multi-Criteria Decision Analysis (MCDA) inter- dependence of the following criteria will be explored: efficacy, budget impact, safety, unmet need, strategic, patient preference, equity and severity. Introduction to each criteria will be provided to the audience. Scoring comparison between different countries will be performed. Presenters will demonstrate Rare Disease MCDA criteria transferability and application across European countries. Audience engagement is anticipated during the meeting.
Presented by ISPOR CEE Consortium and ISPOR Italy-Rome Chapter


18:15 - 19:15
Room: Forth (Armadillo)
F6: THE ESTABLISHMENT OF NEGOTIATION COMMITTEE, THERAPEUTIC GUIDELINES AND HEALTH TECHNOLOGY ASSESSMENT EFFORTS IN CEE COUNTRIES
Moderator:

Magda Hatzikou, PhD, Managing Partner, PharmEcons Easy Access Ltd, Athens, Greece

Speakers:

Zoltan Kalo, PhD, Professor of Health Economics, Eötvös Loránd University (ELTE), Founder & CEO, Syreon Research Institute, Budapest, Hungary

Dragana Atanasijevic, MD, MSc, President, ISPOR Serbia Chapter, Senior Researcher, Institute of Public Health of Serbia, Belgrade, Serbia

Joanna Lis, PhD, Adjunct, Faculty of Pharmacy, Department of Pharmacoeconomics, Medical University of Warsaw, Director, Market Access, Sanofi, Warsaw, Poland

Mary Geitona, MD, Professor, Health Economics, Department of Social and Educational Policy, University of Peloponnese, Korinthos, Greece

DESCRIPTION:

The objective of the panel is to present the benefits of the negotiation committee and the difficulties in the implementation phase, the criteria in decision making and how it will interact with HTA body. Current decision making processes for pharmaceuticals will be described, emphasizing in therapeutic guidelines, reimbursement criteria and functions of negotiation committee. Additionally a proposal of the structure and the criteria of the decision making process of an HTA body will be presented. The proposal was developed by the ISPOR Greece Chapter Board of Directors in an effort to pave the way for the establishment of HTA process which can lead to a sustainable health care system. This forum presentation could be also used as a guide by other CEE countries that are currently in the initiation phase of a Health Technology Assessment organization.
Presented by ISPOR CEE Consortium

Tuesday, 7 November 2017
18:00 - 19:00
BREAKOUT SESSION

18:00 - 19:00
Room: Clyde Auditorium (Armadillo)
F7: HEALTH STATE UTILITY (HSU) IDENTIFICATION AND USE IN COST-EFFECTIVENESS IN DECISION MODELLING - AN ISPOR TASK FORCE
Moderator:

John Brazier, PhD, MSc, Professor of Health Economics and Dean, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

Speakers:

Helene Chevrou-Severac, PhD, HEOR Director, Medical Affairs, Celgene International, Boudry, Switzerland

Roberta Ara, MSc, Senior Research Fellow, School of Health and Related Research, The University of Sheffield, Sheffield, UK

Andrew Lloyd, DPhil, Director, Acaster Lloyd Consulting Ltd., Oxford, UK

DESCRIPTION:

PURPOSE: Utility estimates are an important part of a cost effectiveness analysis and such analyses guide decision making in healthcare around the world. Preference-based measures of health (which are used to estimate utilities) are often not included in clinical trials or such data may be unavailable because health events or states did not occur during the trial. When this happens, a modelling team will need to rely on data from scientific publications. Currently such reviews are commonly not systematic, will combine utilities from different measures and methodologies, and inconsistently adjust for comorbidities and adverse events. Original source documents regularly don’t meet accepted methodological standards. Members of the ISPOR HSU Good Practices Task Force will cover these issues and appropriate methods for identifying, reviewing and synthesising published evidence. In addition, practical matters encountered when using the alternative, applying HSU estimates in decision analytic models, will be discussed.

DESCRIPTION: Issues with using scientific literature include unclear methodology and/or values, use of different measures within the same model, and values that don’t match citations. Problems to address with decision analytic models include: methods used to estimate values for comorbidities or adverse events, appropriately characterising uncertainty when using summary statistics from published evidence, and how to proceed where there is no appropriate or very poor evidence.

Examples of current practices and current methods that are used to identify HSU estimates will be examined along with applying these estimates in cost-effectiveness models, current reporting standards, and the potential impact on the results will be presented. We will argue the case that most cost-effectiveness models should be based on a systematic review of utilities as opposed to using data from a single source. Whether this should be a routine part of HTA submissions will be open for debate.

Presented by ISPOR Health State Utility Good Practices Task Force


18:00 - 19:00
Room: Hall 3
F8: INNOVATION AND MARKET ACCESS IN ASIA-PACIFIC: WHAT EVIDENCE AND PROCESSES ARE APPROPRIATE FOR REIMBURSEMENT? CHINA, JAPAN, SOUTH KOREA, TAIWAN AND AUSTRALIA COMPARED.
Moderator:

Mendel Grobler, B.Pharm, MBA, Director and Head of Health Policy – JAPAC and Emerging Markets, Amgen Inc., North Ryde, NSW, Australia

Speakers:

Shanlian Hu, MS, MD, Senior Consultant, Shanghai Health Development Research Center, Shanghai, China

Bruce Crawford, MPH, MA, Vice President, Real World Evidence & Insights, InVentiv Health Japan G.K., Tokyo, Japan

Sukyeong Kim, PhD, RPh, MPH, Director, Coordinating Center for National Health Clinical Research, National Evidence-Based Healthcare Collaborating Agency, Seoul, Korea, Republic of (South)

Chee-Jen Chang, PhD, MS, President, Taiwan Society for Pharmacoeconomics and Outcome Research, Director, Clinical Informatics and Medical Statistics Research Center, and Professor, Graduate Institute of Clinical Medical Sciences, Chang Gung University, Tao Yuan, Taiwan

DESCRIPTION:

Health technology assessment (HTA) is relatively advanced in the EU, but also developing rapidly in Asia-Pacific. However, the requirements for pharmacoeconomics evidence vary across countries, from well-defined criteria in some countries to not well established or defined in other countries. This forum helps audience to understand new developments and to promote collaboration among different key stakeholders. The forum will provide an overview and case studies of new developments in China, Japan, South Korea, Taiwan and Australia in the following areas:
  • Is HTA/cost-effectiveness nice-to-have or must have? What are the evidence requirements beyond clinical trials?
  • Close collaborations and proactive dialogues across Asia-Pacific countries among key stakeholders
  • The utilization of real-world data to support the decision making in the region
  • Comparisons of the HTA development between EU and Asia countries will be discussed
Presented by ISPOR Asia Consortium Industry Committee


18:00 - 19:00
Room: Hall 1
F9: LATE STAGE ONCOLOGY MCDA CRITERIA IMPLEMENTATION RESULTS IN EUROPEAN COUNTRIES
Moderator:

Vladimir Zah, PhD, Health Economics Consultant and CEO, ZRx Outcomes Research Inc., Belgrade, Serbia

Speakers:

Oresta Piniazhko, PhD, President, ISPOR Ukraine Chapter, Assistant Professor, Member of Expert Committee of MoH, Department of Management and Economy of Pharmacy, Medicine Technology and Pharmacoeconomics, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

Niki Popper, Dipl.Ing., Dr., President, ISPOR Austria Chapter, Professor, University of Technology Vienna, Vienna, Austria

Aleksandra Zawodnik, MSc Pharm, PhD Candidate, Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland

Bertalan Nemeth, MSc, Senior Pharmacoeconomist, Syreon Research Institute, Budapest, Hungary

DESCRIPTION:

Late stage oncology Multi-Criteria Decision Analysis (MCDA) inter- dependence of the following criteria will be explored: efficacy, budget impact, safety, unmet needs, strategic & patient preference. Introduction to each criteria will be provided to the audience. Scoring comparison between different countries will be performed. Presenters will demonstrate late stage oncology MCDA criteria transferability and application across European countries. Audience engagement is anticipated during the meeting.
Presented by ISPOR CEE Consortium and ISPOR Austria Chapter


18:00 - 19:00
Room: Forth (Armadillo)
F10: THE BURDEN OF COPD IN CENTRAL & EASTERN EUROPE
Moderator:

Maria Kamusheva, PhD, Assistant Professor, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria

Speakers:

Josip Culig, MD, PhD, Professor, Pharmacology & Clinical Pharmacology & Head, Pharmacoepidemiology Department, Andrija Stampar Institute of Public Health, Zagreb, Croatia

Konstantin Tachkov, PhD(c), PhD student, Medical University of Sofia, Sofia, Bulgaria

Tamas Agh, MD, MSC, PhD, Principal Researcher, Syreon Research Institute, Hungary, Hungary

Mary Geitona, MD, Professor, Health Economics, Department of Social and Educational Policy, University of Peloponnese, Korinthos, Greece

DESCRIPTION:

Chronic obstructive pulmonary disease (COPD) is a major health problem in CEE countries being the second most frequently diagnosed disease. High prevalence of smoking and environmental factors are the most common causes of COPD in the region. Modern treatments are often applied with delay and hence patients adherence to therapy is lower. The health needs of affected population and economic burden of COPD requires thorough investigation. The aim of this forum is to highlight the social and economic burden of COPD and its therapy in the CEE region.
Presented by ISPOR CEE Consortium


18:00 - 19:00
Room: Lomond Auditorium (Loch Suite)
F11: THE NEW PARADIGM OF CANCER TREATMENTS: A CHALLENGE FOR THE HEALTH SYSTEMS?
Moderator:

Carme Pinyol, MD, PhD, MSc, President, ISPOR Spain Chapter, Head of Pricing and Market Access Southern Europe, Pierre Fabre, Barcelona, Spain

Speakers:

César Hernández, PhD, Head of the Department of Drugs of Human Use, Spanish Agency of Medicines and Health Products, Barcelona, Spain

Jorge Mestre-Ferrandiz, PhD, Consultant, Expert in Pharmacoeconomics, OHE Collaborator, Madrid, Spain

DESCRIPTION:

Spain is facing new challenges in the oncology field:

- New molecules are going to have a diverse range of indications for different tumor types. This will be in therapy areas with existing products and those with few effective treatments, and these will be in indications for small patient populations (orphan) and for non-orphan diseases.

- This medicines are considered to be “expensive drugs” and will be launch into an environment already concerned with the price of new medicines

From the payers perspective this situation implies some significant challenges; they have concerns and in particular, they are worried about the products that will be launched at high prices and, because of new indications, the patient population and the associated volume will be expanded significantly, putting pressure on their budget. This encourages payers to re-negotiate the price of the products for each new indication or to use capitation systems limiting the patient population candidate to use the product reimbursed. The result of this would be a series of sequential price negotiations and a downward spiral in terms of the price. The goal of this forum will be to discuss what will happen with the future oncology pipeline from a relative effectiveness perspective, and to consider the possible models to cushion the impact that will produce in the health systems. For this purpose, we will have a person representing the Spanish Agency of Medicines and Health Products and the experience of a health economist who works in a European project with models of chronicity, and given that oncology is becoming, with the new therapies, a chronic pathology.

Presented by ISPOR Spain Chapter


18:00 - 19:00
Room: Hall 2
F12: IMPLEMENTING ADAPTIVE PATHWAYS IN EUROPE: A CENTRAL AND EASTERN EUROPE (CEE) FOCUS
Moderator:

André Broekmans, MD, PhD, Director Escher, Lygature and Coordinator, ADAPT SMART, Utrecht, The Netherlands

Speakers:

Zoltan Kalo, PhD, Professor of Health Economics, Eötvös Loránd University (ELTE), Founder & CEO, Syreon Research Institute, Budapest, Hungary

Tomas Tesar, PharmD, PhD, MBA, MPH, MSc, Member of the Reimbursement Committee, Slovak Ministry of Health, Union Health Insurance Fund, Bratislava, Slovakia

Dominik Tomek, PharmD, MPH, PhD, President, ISPOR Slovakia Chapter, and Senior Researcher, Faculty of Medicine, Slovak Medical University, Bratislava, Slovak Republic

DESCRIPTION:

Adaptive pathways is a scientific concept for medicine development and data generation which allows for early and progressive patient access to a medicine. The approach makes use of the existing European Union (EU) regulatory framework for medicines. Adaptive pathways is based on three principles: iterative development, gathering evidence through real-life use to supplement clinical trial data, early involvement of patients and health-technology-assessment bodies/payers in discussions on a medicine's development. In this session, we want to discuss the opportunities and potential challenges for implementing the adaptive pathways concept in Europe, with a specific focus on CEE countries. The session is hosted by the ADAPT SMART consortium. The consortium brings together patients, regulators, industry, health technology assessment (HTA) bodies, payers, and academics to identify more efficient ways of developing and regulating medicines and provide patients with timely access to beneficial medicines access to innovative medicines.
-

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.